In today’s briefing:
- Mirxes Pre-IPO: Early Signs of Commercialization Challenges
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Mirxes Pre-IPO: Early Signs of Commercialization Challenges
- Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.
- In this insight, we examine its key product, GASTROClear’s technical and clinical data. We also look at the competitive landscape.
- We are of the view that the company’s product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.